{"id":"mfolfox6-plus-cetuximab","safety":{"commonSideEffects":[{"rate":"30-50%","effect":"Diarrhea"},{"rate":"20-40%","effect":"Fatigue"},{"rate":"20-40%","effect":"Nausea"},{"rate":"10-30%","effect":"Neutropenia"},{"rate":"10-30%","effect":"Anemia"}]},"_chembl":{"chemblId":"CHEMBL1201577","moleculeType":"Antibody"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"The mFOLFOX6 regimen consists of oxaliplatin, 5-fluorouracil, and leucovorin, which work together to inhibit DNA synthesis and induce apoptosis in cancer cells. Cetuximab, a monoclonal antibody, targets the epidermal growth factor receptor (EGFR), preventing it from promoting cell proliferation and survival.","oneSentence":"mFOLFOX6 plus cetuximab is a chemotherapy regimen that targets cancer cells by inhibiting DNA synthesis and inducing apoptosis.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:21:15.383Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic colorectal cancer"},{"name":"Advanced squamous cell carcinoma of the head and neck"}]},"trialDetails":[{"nctId":"NCT05355701","phase":"PHASE1","title":"A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations.","status":"RECRUITING","sponsor":"Pfizer","startDate":"2022-07-05","conditions":"Melanoma, Non-Small-Cell Lung Cancer, Thyroid Cancer","enrollment":267},{"nctId":"NCT06997497","phase":"PHASE3","title":"A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-07-16","conditions":"Colon Adenocarcinoma, Rectal Adenocarcinoma","enrollment":477},{"nctId":"NCT06662786","phase":"PHASE3","title":"A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer","status":"RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2024-10-18","conditions":"Colorectal Neoplasms","enrollment":1000},{"nctId":"NCT05253651","phase":"PHASE3","title":"A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer","status":"RECRUITING","sponsor":"Seagen, a wholly owned subsidiary of Pfizer","startDate":"2022-10-24","conditions":"Colorectal Neoplasms","enrollment":400},{"nctId":"NCT06445062","phase":"PHASE1, PHASE2","title":"Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors","status":"RECRUITING","sponsor":"Revolution Medicines, Inc.","startDate":"2024-05-24","conditions":"Colorectal Cancer, CRC, Pancreatic Ductal Adenocarcinoma","enrollment":1130},{"nctId":"NCT06011772","phase":"EARLY_PHASE1","title":"EGF-Depleting Therapy CIMAvax-EGF in Combination With Standard Therapy for RAS- and BRAF Wild-Type Metastatic Colorectal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Roswell Park Cancer Institute","startDate":"2023-12-18","conditions":"Colo-rectal Cancer","enrollment":2},{"nctId":"NCT05239741","phase":"PHASE3","title":"Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Chinese Participants With Stage IV Colorectal Cancer (MK-3475-C66)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2022-04-02","conditions":"Colorectal Neoplasms","enrollment":100},{"nctId":"NCT07391618","phase":"PHASE2","title":"Clinical Study on the First-line Treatment of Advanced Colorectal Cancer With Simultaneous Infusion of Levozolinate for Injection and 5-FU","status":"RECRUITING","sponsor":"Chinese PLA General Hospital","startDate":"2025-05-15","conditions":"Advanced Colorectal Cancer","enrollment":583},{"nctId":"NCT06771622","phase":"PHASE1, PHASE2","title":"Safety and Efficacy of HCB101 in Combination With Multiple Agents in Patients With Advanced Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"FBD Biologics Limited","startDate":"2025-03-13","conditions":"Solid Cancer","enrollment":500},{"nctId":"NCT05959356","phase":"PHASE2","title":"Cetuximab and Envafolimab Plus mFOLFOXIRI as First-line Treatment for RAS/BRAF Wild-type, MSS, Unresectable Left-side Metastatic Colorectal Cancer","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2023-11-09","conditions":"Metastatic Colorectal Cancer","enrollment":198},{"nctId":"NCT06385925","phase":"PHASE1, PHASE2","title":"A Study of TSN1611 Treating Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation","status":"RECRUITING","sponsor":"Tyligand Pharmaceuticals (Suzhou) Limited","startDate":"2024-04-29","conditions":"Malignant Neoplasm","enrollment":440},{"nctId":"NCT04835142","phase":"PHASE3","title":"Comparison of A140 and Erbitux Combined With mfolfox6 to Evaluate Efficacy and Safety of First-line Treatment for Ras Wild-type mCRC","status":"COMPLETED","sponsor":"Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.","startDate":"2020-12-31","conditions":"Metastatic Colorectal Cancer","enrollment":688},{"nctId":"NCT02671435","phase":"PHASE1, PHASE2","title":"A Study of Durvalumab (MEDI4736) and Monalizumab in Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"MedImmune LLC","startDate":"2016-02-22","conditions":"Advanced Solid Tumors","enrollment":383},{"nctId":"NCT07000305","phase":"PHASE2","title":"A Study of Cetuximabβ Combined With Envolimab and mFOLFOX6 in Subjects With Advanced Colorectal Cancer","status":"NOT_YET_RECRUITING","sponsor":"Tao Zhang","startDate":"2025-05-20","conditions":"Advanced Colorectal Cancer","enrollment":42},{"nctId":"NCT06978400","phase":"PHASE2","title":"A Study of Dabrafenib Plus Cetuximab/Panitumumab With FOLFOX in the First Line of Therapy in People With Metastatic Colorectal Cancer","status":"RECRUITING","sponsor":"Blokhin's Russian Cancer Research Center","startDate":"2025-03-01","conditions":"Neoplasms","enrollment":64},{"nctId":"NCT06908031","phase":"PHASE2","title":"SCRT + mFOLFOX6 + PD-1 Antibody + Targeted Therapy for HIgh-Risk pMMR/MSS Rectal Cancer","status":"RECRUITING","sponsor":"Sixth Affiliated Hospital, Sun Yat-sen University","startDate":"2025-04-02","conditions":"Rectal Adenocarcinoma, High-Risk Cancer, MSS","enrollment":49},{"nctId":"NCT06959693","phase":"PHASE2, PHASE3","title":"A Clinical Study to Evaluate the Efficacy and Safety of Envafolimab Combined With Cetuxima-βand mFOLFOX6 in Patients With MSS, RAS/BRAF Wild-Type Metastatic Colorectal Cancer (mCRC)","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2025-06-01","conditions":"Metastatic Colorectal Cancer (CRC)","enrollment":590},{"nctId":"NCT06521866","phase":"PHASE2","title":"Phase II Study of Serplulimab Combined with First-Line Targeted Therapy, Chemotherapy, and Radiation in Advanced Colorectal Cancer","status":"RECRUITING","sponsor":"Fudan University","startDate":"2025-03-01","conditions":"Advanced Colorectal Carcinoma, Immunotherapy","enrollment":208},{"nctId":"NCT04793958","phase":"PHASE3","title":"Phase 3 Study of MRTX849 With Cetuximab vs Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation (KRYSTAL-10)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Mirati Therapeutics Inc.","startDate":"2021-06-24","conditions":"Advanced Colorectal Cancer, Metastatic Colorectal Cancer","enrollment":461},{"nctId":"NCT06776757","phase":"PHASE1, PHASE2","title":"Sintilimab in Combination with Cetuximab and Chemotherapy As First-line Treatment for RAS/BRAF Wild-type Advanced Colorectal Cancer","status":"RECRUITING","sponsor":"Cancer Hospital Chinese Academy of Medical Science, Shenzhen Center","startDate":"2023-12-25","conditions":"Metastatic Colorectal Cancer","enrollment":30},{"nctId":"NCT01167725","phase":"PHASE3","title":"Standard Therapy With or Without Surgery and Mitomycin C in Treating Patients With Advanced Limited Peritoneal Dissemination of Colon Cancer","status":"TERMINATED","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2010-08","conditions":"Colorectal Cancer","enrollment":340},{"nctId":"NCT02563002","phase":"PHASE3","title":"Study of Pembrolizumab (MK-3475) vs Standard Therapy in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Carcinoma (MK-3475-177/KEYNOTE-177)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2015-11-30","conditions":"Colorectal Carcinoma","enrollment":307},{"nctId":"NCT05628038","phase":"PHASE2","title":"The Combination of Hypofractionated Radiotherapy and Immunotherapy in Locally Recurrent Rectal Cancer","status":"RECRUITING","sponsor":"Fudan University","startDate":"2022-11-30","conditions":"Recurrent Rectal Cancer","enrollment":93},{"nctId":"NCT06616259","phase":"PHASE3","title":"First-line Treatment of MCapOX + Cetuximab Vs. MFOLFOX6 + Cetuximab for RAS/BRAF Wild-type, MSS, Unresectable Left-Sided MCRC: a Multicenter, Randomized, Controlled, Phase III Study","status":"NOT_YET_RECRUITING","sponsor":"Meng Qiu","startDate":"2024-09-26","conditions":"Colorectal Cancer (CRC), Capecitabine, Cetuximab","enrollment":452},{"nctId":"NCT06590259","phase":"PHASE2","title":"A Study on the Efficacy and Safety of Multi-mode Ablation Combined With Systemic Therapy in the Treatment of CRCLM","status":"RECRUITING","sponsor":"Shanghai 6th People's Hospital","startDate":"2024-03-12","conditions":"Colorectal Cancer Liver Metastasis","enrollment":20},{"nctId":"NCT06322147","phase":"","title":"Chemotherapy With Cetuximab as Conversion Therapy in RAS/BRAF WT Unresectable Liver Metastasis Right-sided Colon Cancer","status":"UNKNOWN","sponsor":"Qilu Hospital of Shandong University","startDate":"2023-06-01","conditions":"Colon Cancer","enrollment":50},{"nctId":"NCT01910610","phase":"PHASE3","title":"Multi-Line Therapy Trial in Unresectable Metastatic Colorectal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"GERCOR - Multidisciplinary Oncology Cooperative Group","startDate":"2013-10-30","conditions":"Colorectal Cancer Metastatic","enrollment":464},{"nctId":"NCT05022030","phase":"PHASE2","title":"First-line mCapOX+Cetuximab vs. mFOLFOX6+Cetuximab for Metastatic Left-sided CRC With Wild-type RAS/BRAF Genes","status":"RECRUITING","sponsor":"West China Hospital","startDate":"2021-07-21","conditions":"Colo-rectal Cancer, Capecitabine, Cetuximab","enrollment":150},{"nctId":"NCT04923620","phase":"","title":"Neoadjuvant Cetuximab + Chemotherapy Combined With Short-course Radiotherapy","status":"UNKNOWN","sponsor":"Shanghai Minimally Invasive Surgery Center","startDate":"2021-10-20","conditions":"Neoadjuvant Treatment, Rectal Cancer, Cetuximab","enrollment":51},{"nctId":"NCT05948072","phase":"PHASE3","title":"Cetuximab+mFOLFOX6 VS. mFOLFOX6 Alone in RAS/BRAF Wild Type Patients With High-Risk Resectable CRLM","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2023-07-15","conditions":"Colorectal Cancer, Liver Metastases","enrollment":250},{"nctId":"NCT05652894","phase":"PHASE3","title":"A Study of HX008 Compared to Chemotherapy in the First-Line Treatment of Subjects With MSI-H/dMMR Metastatic Colorectal Cancer","status":"NOT_YET_RECRUITING","sponsor":"Taizhou Hanzhong biomedical co. LTD","startDate":"2022-12-20","conditions":"Metastatic Colorectal Cancer","enrollment":190},{"nctId":"NCT03174405","phase":"PHASE2","title":"Avelumab and Cetuximab in Combination With FOLFOX in Patients With Previously Untreated Metastatic Colorectal Cancer - The Phase II AVETUX-CRC Trial.","status":"COMPLETED","sponsor":"AIO-Studien-gGmbH","startDate":"2017-07-17","conditions":"Metastatic Colorectal Cancer","enrollment":43},{"nctId":"NCT01307878","phase":"PHASE3","title":"New Adjuvant Chemotherapy of Asymptomatic Resectable Primary Lesion With Unresectable Liver-limited Metastases","status":"COMPLETED","sponsor":"Fudan University","startDate":"2012-06","conditions":"Colorectal Neoplasms, Neoplasm Metastasis, Liver Neoplasms","enrollment":320},{"nctId":"NCT00193219","phase":"PHASE2","title":"Bevacizumab and Cetuximab in Combination With FOLFOX6 in Patients With Metastatic Colorectal Cancer","status":"COMPLETED","sponsor":"SCRI Development Innovations, LLC","startDate":"2005-07","conditions":"Colon Cancer","enrollment":36},{"nctId":"NCT01442649","phase":"PHASE2","title":"Efficacy of Chemotherapy, Associated to Either Cetuximab or Bevacizumab, in KRAS Wild-type Metastatic Colorectal Cancer Patients With Progressive Disease After Receiving First-line Treatment With Bevacizumab","status":"COMPLETED","sponsor":"UNICANCER","startDate":"2010-12","conditions":"Colorectal Cancer","enrollment":133},{"nctId":"NCT04466254","phase":"PHASE2","title":"Efficacy and Safety Study of Combination of CPGJ602 and Chemotherapy, in First Line, With Wild KRAS/NRAS/BRAF in Metastatic Colorectal Cancer","status":"UNKNOWN","sponsor":"Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.","startDate":"2020-12-07","conditions":"Metastatic Colorectal Cancer","enrollment":75},{"nctId":"NCT02942706","phase":"PHASE2, PHASE3","title":"Cetuximab Maintenance Treatment Versus Continuation After Induction Therapy in mCRC","status":"UNKNOWN","sponsor":"Ruijin Hospital","startDate":"2021-11","conditions":"Colorectal Cancer","enrollment":200},{"nctId":"NCT04718038","phase":"","title":"Continuing Cetuximab Plus Chemotherapy After First Progression in Wild-type KRAS, NRAS and BRAF V600E Metastatic Colorectal Cancer","status":"COMPLETED","sponsor":"Henan Cancer Hospital","startDate":"2016-07-01","conditions":"Wild-type KRAS,NRAS and BRAF V600E Metastatic Colorectal Cancer","enrollment":60},{"nctId":"NCT01867697","phase":"PHASE2","title":"Nordic 8 - A Phase II Trial","status":"COMPLETED","sponsor":"Per Pfeiffer","startDate":"2012-05","conditions":"Metastatic Colorectal Cancer","enrollment":173},{"nctId":"NCT01923987","phase":"PHASE2","title":"Short Course Radiotherapy Followed Intensive Chemotherapy With Delayed Surgery for Rectal Cancer With Synchronous Distant Metastasis","status":"UNKNOWN","sponsor":"Korea Cancer Center Hospital","startDate":"2012-08","conditions":"Rectal Cancer, Liver Metastasis, Lung Metastasis","enrollment":39},{"nctId":"NCT01836653","phase":"PHASE2","title":"Achievement of Improved Survival by Molecular Targeted Chemotherapy and Liver Resection for Not Optimally Resectable Colorectal Liver Metastases","status":"COMPLETED","sponsor":"EPS Corporation","startDate":"2013-05","conditions":"Liver Only Metastasis From KRAS Exon 2 Wild Type (Under Protocol 1.0-1.2 Edition) and RAS Wild Type (Under Protocol 2.0 Edition) Colorectal Cancer","enrollment":122},{"nctId":"NCT01834014","phase":"NA","title":"Exploratory Study in Achievement of Improved Survival by Molecular Targeted Chemotherapy and Liver Resection for Not Optimally Resectable Colorectal Liver Metastases","status":"COMPLETED","sponsor":"EPS Corporation","startDate":"2013-05","conditions":"Liver Metastasis, Colorectal Cancer","enrollment":110},{"nctId":"NCT02978313","phase":"PHASE2, PHASE3","title":"Cetuximab Monotherapy Maintenance Treatment in mCRC","status":"UNKNOWN","sponsor":"Ruijin Hospital","startDate":"2016-11","conditions":"Colorectal Cancer","enrollment":500},{"nctId":"NCT00811993","phase":"PHASE1","title":"A Study of R1507 in Combination With Multiple Standard Chemotherapy Treatments in Patients With Advanced Solid Tumors","status":"TERMINATED","sponsor":"Hoffmann-La Roche","startDate":"2009-02","conditions":"Neoplasms","enrollment":104},{"nctId":"NCT01338558","phase":"PHASE3","title":"A Study of Avastin (Bevacizumab) in Combination With mFOLFOX6 in Treatment-Naïve Patients With Metastatic Colorectal Cancer With or Without K-RAS Mutations, and Comparison to Cetuximab","status":"WITHDRAWN","sponsor":"Hoffmann-La Roche","startDate":"2011-06","conditions":"Colorectal Cancer","enrollment":""},{"nctId":"NCT01161316","phase":"PHASE2","title":"Safety and Efficacy Study of mFOLFOX-6 Plus Cetuximab for 8 Cycles Followed by mFOLFOX-6 Plus Cetuximab or Single Agent Cetuximab as Maintenance Therapy in Patients With Metastatic Colorectal Cancer and WT KRAS Tumours","status":"COMPLETED","sponsor":"Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)","startDate":"2010-08","conditions":"Metastatic Colorectal Cancer","enrollment":194},{"nctId":"NCT01564810","phase":"PHASE4","title":"Cetuximab in Combination With Chemotherapy for the Treatment of Metastatic Colorectal Cancer","status":"UNKNOWN","sponsor":"Xu jianmin","startDate":"2006-09","conditions":"Colorectal Neoplasms, Neoplasm Metastasis, Liver Neoplasms","enrollment":150},{"nctId":"NCT01322178","phase":"PHASE2","title":"Study of Cetuximab in Combination With mFOLFOX-6 (Oxaliplatin, Leucovorin, 5-FU) to Treat Colorectal Liver Metastatic Cancer Patients","status":"UNKNOWN","sponsor":"Fudan University","startDate":"2010-12","conditions":"Colorectal Cancer, Liver Metastases","enrollment":90}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"mFOLFOX6 plus cetuximab","genericName":"mFOLFOX6 plus cetuximab","companyName":"West China Hospital","companyId":"west-china-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"mFOLFOX6 plus cetuximab is a chemotherapy regimen that targets cancer cells by inhibiting DNA synthesis and inducing apoptosis. Used for Metastatic colorectal cancer, Advanced squamous cell carcinoma of the head and neck.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}